NeuroBytes: Acute Symptomatic Seizures
Course Description
With the expanding use of inpatient continuous EEG, more non-convulsive seizures and other highly epileptiform patterns are being uncovered. In the acute phase, patients are appropriately treated with antiseizure medications (ASMs), but patients often remain on medications for years; possibly unnecessarily and with risk of adverse effects, long-term toxicity, and drug interactions. This course will explore factors which place patients in higher or lower risk strata for long-term epilepsy and thereby help guide management decisions for continuation versus weaning of ASMs.
Learning Objectives
As a result of this program the learner will be able to:
- Define acute symptomatic seizures
- Compare the risk of epilepsy between unprovoked and acute symptomatic seizures
- Recognize features which increase the risk of epilepsy following acute symptomatic seizures
- Describe a reasonable approach to anti-seizure medication discontinuation in the post-acute period
Date of Release
December 23, 2023
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved. See complete
Terms of Use.
Faculty & Disclosures
HARRY W. SUTHERLAND, MD
Clinical Neurophysiology/Epilepsy Fellow
Department of Neurology, Epilepsy Division
Yale University School of Medicine
New Haven, CT
* Dr. Sutherland has received personal compensation in the range of $0-$499 for serving as a Consultant for McGraw-Hill.
Editor
Reviewer
Clinical Neurophysiology/Epilepsy Fellow
Department of Neurology, Epilepsy Division
Yale University School of Medicine
New Haven, CT
* Dr. Sutherland has received personal compensation in the range of $0-$499 for serving as a Consultant for McGraw-Hill.
Editor
CHRISTOPHER TRANER, MD, MHS
Assistant Professor of Neurology, Epilepsy Division
Assistant Fellowship Director, Clinical Neurophysiology/Epilepsy
Yale University School of Medicine
New Haven, CT
*Dr. Traner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Traner has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Resident Matching Program.
Reviewer
JEREMY MOELLER, MD, FAAN
Professor of Neurology
Yale University
New Haven, CT
*Dr. Moeller has nothing to disclose.
Voiceover Artist
ZACHARY LONDON
Professor
University of Michigan
Ann Arbor, Michigan
*Dr. London has nothing to disclose.
NeuroBytes Staff
Xiaoyu Sun, Associate Director, eLearning
Minneapolis, MN
*Ms. Sun has nothing to disclose.
Robert Rook, Manager, eLearning
Minneapolis, MN
*Mr. Rook has nothing to disclose.